Testing effectiveness (Phase 2)Study completedNCT04281472
What this trial is testing
Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Who this might be right for
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
argenx 322